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and protein expression had a tendency to  increase  in post‐mortem  frontal cortex area 8  (P=0.06 and P=0.08,
respectively). Yet YKL40 immunoreactivity is restricted to a subpopulation of astrocytes in these regions. YKL40
protein  levels, as  revealed by enzyme‐linked  immunosorbent assay  (ELISA), are  significantly  increased  in  the
CSF  in sALS (n=86) compared with age‐matched controls (n=21) (P=0.045). Higher  levels are found  in patients
with fast progression when compared with patients with slow and normal progression (P=0.008 and P=0.004,
respectively),  and  correlates  with  ALS‐FRS‐R  slope  (P=0.000).  Additionally,  increased  protein  levels  of
neurofilament light chain (NF‐L) are also found in sALS (P=0.000); highest values are found in patients with fast
progression when compared with cases with slow and normal progression (P=0.005 and P=0.000, respectively),
and  also  correlate with ALS‐FRS‐R  slope  (P=0.000). Pearson’s  correlation  test  linked positively  the  increased
levels of YKL40 with  increased NF‐L  levels (P=0.013). These data point to YKL40 and NF‐L protein  levels  in the
CSF as a good biomarker combination of disease progression in sALS. 
www.aging‐us.com  2368  AGING 
INTRODUCTION 
 
Chitinase-3-like protein 1 (CHI3L1) or YKL40 is a 
glycoprotein with a molecular weight of about 40 kDa 
that belongs to the family of chitinase-like proteins. 
Chitinases break down glycosidic bonds in chitin, a 
component of the cell wall of fungi and the exoskeleton 
of arthropods [1-5]. YKL40 and other chitinases are 
also localized in various tissues in vertebrates but their 
function is not known; YKL40 shows no chitinase 
activity. Increased expression levels of certain 
chitinases, and particularly of YKL40, are linked to 
inflammation, injury, tissue remodelling and regenera-
tion, angiogenesis, and abnormal cell proliferation in 
tumours [6, 7]. Focusing on neurologic diseases, 
increased YKL40 expression levels have been observed 
in encephalitis, stroke, traumatic brain injury, multiple 
sclerosis, and glioblastomas [8-17]. YKL40 expression 
is also increased in the cerebrospinal fluid (CSF) in 
neurodegenerative diseases such as Alzheimer’s 
disease, frontotemporal dementia, and Creutzfeldt-
Jakob disease, but not in Parkinson disease or dementia 
with Lewy bodies [18-36]. For this reason, deter-
mination of YKL40 in the CSF has been postulated as a 
new biomarker that may guide diagnosis in par-ticular 
clinical settings. Since YKL40 is mainly expressed in 
astrocytes with only minor expression, if any, in 
microglia, increased YKL40 in CSF is inter-preted as a 
reactive response of astrocytes linked to inflammation 
and regeneration [33,37-40].  
 
Chitinases have also been assessed in the brain and 
biological fluids in amyotrophic lateral sclerosis (ALS). 
Chitotriosidase (CHIT1) activity is increased in blood in 
ALS cases when compared with controls, and CHIT1 
levels are higher in patients with rapid progression [41]. 
Furthermore, CHIT1 is increased in microglia and 
macrophages in spinal cord in ALS, and CSF levels 
correlate with disease severity and progression [42]. 
YKL40 and chitinase-3-like protein 2 (CHI3L2) mRNA 
levels are increased in the motor cortex in ALS [43]. 
Finally,   as   determined  with  liquid  chromatography/ 
tandem mass spectrometry, elevated CHIT1, YKL40, 
and CHI3L2 levels in the CSF correlate with disease 
progression in ALS [44]. A parallel work presented by 
another group at the ALS Society Meeting (Amsterdam 
June 7-8, 2018) reported increased YKL40 in the CSF 
along the ALS-FTD spectrum [45].   
 
The present study examines YKL40 mRNA and protein 
expression in brain, YKL40 mRNA levels in blood, and 
protein levels in the CSF in cases of sporadic ALS 
(sALS) to learn about the relation between mRNA and 
protein levels in the central nervous system, and those 
in CSF and peripheral blood. Based on the previous 
observations in several diseases, it is worth to have in 
mind that that YKL40 is not looked as a putative 
specific biomarker of ALS but as a potential biomarker 
of prognosis. Therefore, the present study was geared to 
learn about the use of YKL40 as a possible biomarker 




Increased CHI3L1 mRNA expression levels in the 
anterior horn of the spinal cord and frontal cortex in 
sALS 
 
Significantly increased expression of CHI3L1 was 
found in the anterior horn of the spinal cord (P=0.004) 
in sALS (Figure 1A). Levels of transcripts coding for 
the main markers of astrocytes and microglia were also 
assessed in the anterior horn of the spinal cord. 
Significantly up-regulated levels of microglial markers 
AIF1 and CD68 were detected in the spinal cord in 
sALS (P=0.044 and P=0.000, respectively) (Figure 
1B), which significantly correlated with CHI3L1 
mRNA expression (P=0.043 and P=0.025, respec-
tively). However, GFAP and ALDH1L1 mRNA levels 
did not show differences between sALS and control 
cases (P=0.22 and P=0.77, respectively) (Figure 1B). 
No correlations were detected with CHI3L1 expression 
(P=0.66 and P=0.88, respectively) in the spinal cord 
region.  
 
CHI3L1 mRNA expression had a tendency to increase 
in the frontal cortex area 8 in sALS (P=0.06) (Figure 
1A). No changes were observed in the mRNA levels of 
AIF1 (P=0.32), CD68 (P=0.89), GFAP (P=0.15), and 
ALDH1L1 (P=0.15) in sALS (Figure 1B). Finally, no 
correlations were found between CHI3L1 mRNA levels, 
and astrocytic and microglial markers in frontal cortex 
area 8 of sALS cases. 
 
Protein levels of YKL40 are increased in frontal 
cortex area 8 in sALS  
 
Western blotting showed a tendency to increase YKL40 
and IBA1 protein levels in the anterior horn of the 
spinal cord of sALS when compared with controls 
(P=0.08 and P=0.07, respectively). GFAP protein levels 
were significantly increased, particularly breakdown 
products (BDP) (P=0.01) in the spinal cord of sALS 
when compared with controls (Figure 1C). Increased 
GFAP low molecular weight bands (BDPs) have been 
previously reported in ALS [46]. In contrast, a 
significant increase in YKL40 (P=0.03) and GFAP 
(P=0.02) levels, but not in IBA1 (P=0.62), was found 
in frontal cortex area 8 in sALS when compared with 
controls (Figure 1C). YKL40 immunoreactivity was 
restricted to astrocytes in the frontal cortex and spinal 
cord in sALS and control cases (Figure 1D).  


















































































































cases. CHI3L1  is  significantly up‐regulated  in  the anterior  spinal  cord but has only a  tendency  to  increase without  significance  in  the
frontal  cortex  in  sALS  compared with  controls.  (B) mRNA  expression  levels  of microglial  (CD68  and  AIF1)  and  astroglial  (GFAP  and
ALDH1L1) markers  in  the anterior horn of  lumbar  spinal  cord and  frontal  cortex area 8  in  sALS and age‐matched  controls. Microglial
markers CD68 and AIF1 are significantly up‐regulated  in  the anterior horn of  the spinal cord but not  in  the  frontal cortex  in sALS. The
mRNA expression levels of astroglial markers in the spinal cord and frontal cortex are not modified in pathological cases when compared
with controls. (C) Western blot analysis of YKL40 in the spinal cord (left panel) and frontal cortex area 8 (right panel) of control and sALS;
β‐actin  was  used  for  normalization.  Graphical  representation  of  western  blot  data;  fold  changes  in  the  expression  of  protein  are
determined relative to the control cases. YKL40 and GFAP protein levels are increased in the spinal cord and frontal cortex in sALS when
compared with controls. Due  to  individual variation,  increased values  in  the anterior horn of  the spinal cord showed only a  tendency
without  statistical  significance.  In  contrast,  expression  levels  were  not  significantly  modified  in  sALS.  *P < 0.05,  **P < 0.01,  and
***P < 0.001, tendency #P<0.1. (D) YKL40 expression in frontal cortex area 8 (a, b) and spinal cord (c, d) in control (a, c) and sALS (b, d)
cases) is found in astrocytes; immunohistochemical sections lightly counterstained with haematoxylin, bar = 25μm. 


















































Levels of YKL40 are increased in CSF of sALS 
patients and correlate with ALS-FRS evolution and 
fast disease progression 
 
Significantly higher YKL40 levels were detected in 
sALS cases (465.41 ± 13.45 pg/mL) compared with 


















































To calculate the clinical accuracy of YKL-40 in 
discriminating between sALS and the control group, we 
estimated the AUC value (AUC: 0.6254, 95% CI: 0.52–
0.72) (Figure 2B). Considering the optimal cut-off at 
356.24pg/mL, defined by the Youden index, an overall 
sensitivity of 80% and specificity of 43% can be 
predicted. To demonstrate possible relations between 
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increased levels of YKL40 and the main clinical 
parameters, Pearson's correlation or parametric 
comparisons tests were applied. Clinical parameters 
such as age, gender, disease onset, disease progression, 
signs of frontotemporal lobar degeneration, and ALS-
FRS-R score were examined. Pearson’s correlation 
indicated a significant link between age and YKL40 
levels, increasing with age in controls and sALS 
(P=0.000). Additionally, Pearson’s correlation test 
demonstrated a positive correlation between ALS-FRS-
R slope and YKL40 levels in CSF (P=0.004) (Figure 
2C). Based on these observations, YKL40 levels were 
studied in function of the disease progression in every 
patient; a significant increase in YKL40 CSF levels was 
identified in those patients with fast progression when 
compared with patients with slow and normal prog-
ression (P=0.008 and P=0.004, respectively) (Figure 
2D). Since at the end of the study only 28 of the 86 
sALS cases assessed had died, no attempt was made to 
analyze the relationship between YKL40 levels in the 




































CHI3L1 mRNA levels in blood 
 
Additionally, CHI3L1 mRNA levels were analyzed in 
whole peripheral blood samples of sALS at the time of 
diagnosis. Despite the relatively small number of 
control and disease cases, individual variations were 
frequent in the two groups and accounted for the lack of 
significant changes between control and sALS cases 
(Figure 2E). 
 
Levels of NF-L are increased in CSF of sALS 
patients and correlate with ALS-FRS-R slope 
evolution, fast disease progression and YKL40 levels 
 
Neurofilament light chain (NF-L) levels were quantified 
in CSF of the same cohort of control and sALS cases. 
Significant higher NF-L levels were detected in sALS 
cases (4637.55 ± 192.31pg/mL) compared with controls 
(610.36 ± 81.11pg/mL) (P=0.000) (Figure 3A). 
Additionally, NF-L levels were correlated with ALS-





































found  in  cases with  fast progression  (FP) when  compared with  cases with  slow and normal progression  (SP and NP,  respectively;
P = 0.000, P = 0.005). (D) Positive correlation between YKL40 levels (pg/mL) and NF‐L levels (pg/mL) (Pearson’s correlation, P=0.013). 
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was found between ALS-FRS-R and NF-L levels in 
CSF (P=0.000) (Figure 2B). NF-L levels were 
significantly increased in patients with fast progression 
when compared with patients with slow and normal 
progression (P=0.000 and P=0.005, respectively) 
(Figure 2C). Finally, positive significant correlation was 
observed between YKL40 and NF-L levels (Pearson’s 




Inflammation involving microglial cells, macrophages, 
T cells, astrocytes, and neurons, and mediated by a 
plethora of mediators of the immune response including 
Toll-like receptors, members of the complement system, 
pro- and anti-inflammatory cytokines, chemoquines, 
and blood vessel factors, are activated in the anterior 
horn of the spinal cord and, to a lesser extent, in other 
brain regions in ALS [47-59]. 
 
Increased protein levels of several cytokines and 
mediators of the inflammatory response have also been 
reported in the CSF in ALS, including IL-1, IL-1β, IL-
6, IL-8, IL-12, IL-15, IL-17A, IL-18BP, IL-23, 
RANTES, chemokines, and MCP1 [60-69]. This hetero-
geneous representation indicates variations depending 
on the methods and products employed in the different 
laboratories. Moreover, CSF profiles of angiogenic and 
inflammatory factors are, at least in part, dependent on 
the respiratory status of ALS patients [70]. 
 
Increased levels of selected inflammatory markers are 
found in blood and serum in ALS, thus suggesting 
systemic inflammatory responses which roughly cor-
relate with disease progression [71-80].  
 
All these observations strongly support a role of 
inflammation in the pathogenesis of sALS. However, 
the identification of a biomarker of inflammation with 
practical prognosis value has been limited because of 
individual variation and variations between methods 
and laboratories.       
 
Previous studies in ALS have shown YKL40 mRNA 
up-regulation in the motor cortex [43] and increased 
YKL40 protein levels in the CSF correlating with 
disease progression [44, 45]. Regarding brain tissue, the 
present observations show significant YKL40 mRNA 
up-regulation in the anterior horn of the spinal cord and 
frontal cortex area 8, accompanied by significantly 
increased YKL40 protein levels in the frontal cortex and 
a tendency to increased YKL40 in the spinal cord in 
sALS. Importantly, YKL40 is expressed in astrocytes, 
in agreement with other observations [33, 36-40], but in 
contrast to another description ascribing YKL40 
expression to brain macrophages [44].  
Up-regulation and increased YKL40 expression occcurs 
in parallel with increased values of microglia markers in 
the spinal cord but not in the frontal cortex area in 
sALS, and with increased GFAP protein levels in the 
spinal cord and frontal cortex but not with GFAP 
mRNA up-regulation in these regions.  
 
Together, these observations point to earlier responses 
in astrocytes when compared with microglial reactions 
in the frontal cortex in sALS, whereas microglial 
markers are strongly expressed in the spinal cord in the 
same group of patients. 
 
Based on these findings, increased YKL40 protein 
levels in the CSF mirror YKL40 changes in the central 
nervous system, and they can be interpreted as the 
consequence of YKL40 delivery of astrocytes to the 
CSF. Unfortunately, no analysis of a possible cor-
relation between YKL40 brain and spinal cord values, 
and disease progression/survival, was feasible in the 
present series because of the lack of sufficient clinical 
data. However, YKL40 CSF values negatively correlate 
with patient survival, thus indicating that higher YKL40 
in the CSF likely occurs in patients with rapid disease 
progression.  
 
We do not know at this time what the functional 
implications of elevated YKL40 expression in ALS and 
other neurological diseases are. Nor do we know 
whether YKL40, even considering this particular 
chitinase as a marker of astrocyte inflammation, has 
beneficial or deleterious effects. In this line, chi3l1 KO 
mice have increased astrocytic responses (GFAP 
staining) and increased IBA1 microglial expression 
when compared with wild-type animals following 
traumatic brain injury, thus suggesting that YKL40 
limits the extent of astroglial and microglial neuro-
inflammation [38]. If this is the case then increased 
YKL40 expression per se would not be dangerous but 
rather a manifestation of increased beneficial response 
in the face of a more aggressive facet of ALS in a 
subgroup of patients.  
 
The present findings point to the likelihood that 
increased YKL40 levels in the CSF are not disease 
specific but they are good biomarker of disease 
progression in sALS. 
 
Previous studies have shown increased levels of neuro-
filaments in the CSF of ALS cases [81-84]. NF heavy 
chain levels in CSF were negatively correlated disease 
duration and ALS-FRS-R slope, and NF-L levels 
in CSF were negatively correlated with disease 
duration. Thus, NF heavy and light chain levels have 
potential use as markers of neural degeneration in ALS 
[85, 86]. Increased NF-L in the CSF are not either 
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specific for the disease, but they are more likely used as 
measures of disease progression [85, 86].  
 
In the present work, YKL40 levels in the CSF were 
assessed in parallel with levels of NF light chain. As 
expected, our results are in line with previous 
observations by other authors; NF-light chain levels are 
significantly increased in ALS and levels negatively 
correlate with disease progression and ALS-FRS-R 
slope in our series.  
 
In summary, the present findings point that YKL40 and 
NF-L levels in CSF constitute valuable combination of 
biomarkers for improving accuracy in the prognosis of 
patients with sALS.    
 




Post-mortem fresh-frozen lumbar spinal cord (SC) and 
frontal cortex (FC) (Brodmann area 8) tissue samples 
were obtained from the Institute of Neuropathology 
HUB-ICO-IDIBELL Biobank following the guidelines 
of Spanish legislation on this matter and the approval of 
the local ethics committee. The post-mortem interval 
between death and tissue processing was between 2h 
and 17h. One hemisphere was immediately cut in 
coronal sections, 1-cm thick, and selected areas of the 
encephalon were rapidly dissected, frozen on metal 
plates over dry ice, placed in individual air-tight plastic 
bags, numbered with water-resistant ink, and stored at -
80°C until use for biochemical studies. The other 
hemisphere was fixed by immersion in 4% buffered 
formalin for 3 weeks for morphologic studies. Trans-
versal sections of the spinal cord were alternatively 
frozen at -80°C or fixed by immersion in 4% buffered 
formalin. The anterior horn of the lumbar spinal cord 
was dissected on a dry-ice frozen plate under a 
binocular microscope at a magnification x4.  
 
The neuropathological study was carried out on paraffin 
sections of twenty-six selected regions of the cerebrum, 
cerebellum, brain stem, and spinal cord which were 
stained with haematoxylin and eosin, Klüver Barrera, 
periodic acid shiff, and processed for immunohisto-
chemistry with anti-β-amyloid, phospho-tau (clone AT8), 
α-synuclein, αB-crystallin, TDP-43, ubiquitin, p62, glial 
fibrillary acidic protein, CD68, and IBA1 [87]. All cases 
met the neuropathological criteria for classical ALS 
regarding involvement of motor cortex, pyramidal tracts, 
and selected motor nuclei of the cranial nerves and 
anterior horn of the spinal cord [88, 89]. In addition, 
TDP-43-immunoreactive small dys-trophic neurites and 
TDP-43-positive cytoplasmic neuronal inclusions in 
frontal cortex area 8 were observed in 11 of 18 cases, but 
they were abundant only in three cases (cases 29, 30, and 
31). Spongiosis in the upper cortical layers was found in 
only one case (case 28). Frontotemporal dementia was 
found in no cases of the present series.  
 
Patients with associated pathology including Alzheimer 
disease (excepting neurofibrillary tangle, NFT, 
pathology stages I-II of Braak and Braak), Parkinson 
disease, tauopathies, vascular diseases, neoplastic 
diseases affecting the nervous system, metabolic 
syndrome, hypoxia, and prolonged axonal states such as 
those occurring in intensive care units were excluded. 
Cases with infectious, inflammatory, or autoimmune 
diseases, either systemic or limited to the nervous 
system, were not included. Age-matched control cases 
had not suffered from neurologic or psychiatric 
diseases, and did not have abnormalities in the neuro-
pathological examination excepting NFT pathology 
stages I-II of Braak and Braak. A summary of sALS and 




Cerebrospinal fluid (CSF) was collected prospectively 
from patients undergoing lumbar puncture due to 
clinical suspicion of motor neuron disease at the 
functional unit of amyotrophic lateral sclerosis 
(UFELA) of the Neurology Service of the Bellvitge 
University Hospital. Samples were obtained from 86 
sALS patients (Table 2). In these patients, 1.5 ± 0.5mL 
of CSF was collected in polypropylene tubes as part of 
the clinical routine investigation. CSF was centrifuged 
at 3,000 rpm for 15 min at room temperature. 
Supernatant was collected and aliquoted in volumes of 
250μL and stored at -80ºC until use. All samples were 
analyzed after one freeze/thaw cycle.  
 
Patients were evaluated clinically according to the main 
signs at onset (spinal, bulbar, and respiratory) and 
categorized according to disease progression as fast, 
expected, and slow progression depending on the 
survival or the clinical evolution in those still alive. Fast 
progression was considered in patients who survived 
less than 3 years; normal progression was considered 
between 3 and 5 years, and slow progression for those 
still alive after 5 years. The ALS Functional Rating 
Scale Revised (ALS-FRS-R, version May 2015) was 
used in every case. CSF from control cases was 
obtained from 21 healthy donors following the pro-
tocols for the use of biological samples for research 
(Table 2). No ALS cases or controls suffered from 
infection or inflammatory disorder at the time of 
sampling. CSF samples from sALS cases and age-
matched controls were obtained after signed informed 
consent and approval by the Clinical Research Ethics 
Committee (CEIC) of the Bellvitge University Hospital.  


















































































































      RIN value 
Case Age Gender Diagnosis PM delay Initial symptoms SC FC 
1 49 F Control 07 h 00 min - - 7.2 
2 75 F Control 03 h 00 min - - 7.2 
3 55 M Control 05 h 40 min - - 7.7 
4 59 M Control 12 h 05 min - 6.4 - 
5 59 M Control 07 h 05 min - - 7.8 
6 43 M Control 05 h 55 min - 6.6 7.7 
7 53 M Control 07 h 25 min - - 5.3 
8 56 M Control 03 h 50 min - - 7.6 
9 47 M Control 04 h 55 min - 5.6 7.7 
10 64 F Control 11 h 20 min - 6.2 - 
11 46 M Control 15 h 00 min - 5.9 7.9 
12 56 M Control 07 h 10 min - 6.1 - 
13 71 F Control 08 h 30 min - 5.9 - 
14 64 F Control 05 h 00 min - 7.0 - 
15 79 F Control 06 h 25 min - 6.7 - 
16 75 M Control 07 h 30 min - 5.0 - 
17 55 M Control 09 h 45 min - 5.3 - 
18 52 M Control 03 h 00 min - - 8.3 
19 52 M Control 04 h 40 min - - 6.3 
20 76 M Control 06 h 30 min - 6.6 - 
21 60 F Control 11 h 30 min - - 7.5 
22 51 F Control 04 h 00 min - 6.3 7.9 
23 54 M Control 08 h 45 min - - 7.0 
24 56 M ALS 10 h 50 min NA 7.1 - 
25 70 M ALS 03 h 00 min Respiratory 7.3 7.0 
26 77 M ALS 04 h 30 min NA 7.4 - 
27 56 F ALS 03 h 45 min NA 8.2 7.7 
28 59 M ALS 03 h 15 min NA 7.5 7.7 
29 63 F ALS 13 h 50 min Bulbar 6.8 8.2 
30 59 F ALS 14 h 15 min NA 6.4 6.7 
31 54 M ALS 04 h 50 min Spinal - 7.8 
32 76 M ALS 12 h 40 min Spinal - 7.4 
33 64 M ALS 16 h 30 min NA 6.3 7.3 
34 57 F ALS 04 h 00 min Bulbar 6.2 8.6 
35 75 F ALS 04 h 05 min Bulbar 6.8 6.8 
36 79 F ALS 02 h 10 min NA 7.0 - 
37 57 F ALS 10 h 00 min Bulbar 6.5 7.1 
38 50 M ALS 10 h 10 min Spinal - 5.9 
39 59 F ALS 02 h 30 min Spinal - 7.5 
40 46 M ALS 07 h 00 min Spinal 7.0 8.0 
41 69 F ALS 17 h 00 min Spinal 6.4 6.3 
Abbreviations: F: female; M: male; PM delay: post‐mortem delay; SC: spinal cord; FC: frontal cortex; RIN: RNA integrity number. 














































Whole blood samples were collected using PAXgene 
Blood RNA Tube (PAXgene Blood RNA Tube, 
PreAnalytiX, Qiagen® GmbH, Hilden, GE) collecting 
system. Two PAXgene Blood RNA tubes were obtained 
per case. Samples were collected at the first visit once 
the clinical diagnosis was established (n=12 sALS, 
n=10 controls).Tubes were kept for 2 h at room 
temperature to ensure lysis of blood cells, and then 
stored at −20°C for 24 h. Thereafter, tubes were stored 
at −80°C for at least 7 days prior to processing. A sum-
















































Genetic testing was performed on genomic DNA 
isolated from blood or brain tissue. Informed consent 
for the chromosome9 open reading frame (C9ORF72), 
superoxide dismutase 1 (SOD1), TAR DNA binding 
protein (TARDBP), and FUS RNA binding protein 
(FUS) analysis was obtained from each patient or legal 
representative. Patients in this study did not show 
mutations in the assessed genes.  
Table 3. Summary of cases for whole peripheral blood mRNA studies.  
Case Age Gender Diagnosis Initial symptoms RIN value 
1 60 M Control - 9.1 
2 68 M Control - 9.2 
3 66 F Control - 9.0 
4 N/A M Control - 8.9 
5 74 M Control - 8.0 
6 N/A F Control - 8.3 
7 67 M Control - 6.1 
8 72 F Control - 6.0 
9 44 F Control - 6.0 
10 66 F Control - 6.1 
11 60 M ALS Spinal 7.4 
12 63 M ALS Spinal 8.7 
13 66 F ALS Bulbar 8.9 
14 53 F ALS Bulbar 7.3 
15 73 M ALS Bulbar 8.6 
16 65 M ALS Spinal 8.9 
17 43 M ALS Bulbar 8.6 
18 57 F ALS Bulbar 7.4 
19 65 M ALS Bulbar 7.1 
20 67 M ALS Bulbar 7.4 
21 73 M ALS Spinal 6.1 
22 73 F ALS Spinal 6.0 
Abbreviations: F: female; M: male; NA: not available; RIN: RNA integrity value. 
Table 2. Summary of cases with CSF samples.  
Group    n              Gender Initial symptoms 
Control 21 9 (M) + 12 (F) - 
 
86 47 (M) + 39 (F) 
Spinal 55 
sALS Bulbar 29 
 Respiratory 2 
Abbreviations: F: female; M: male; NA: not available. 
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RNA extraction and RT-qPCR 
 
RNA from dissected frozen anterior horn of the lumbar 
spinal cord (n=14 sALS, n=13 controls) and frontal 
cortex area 8 (n=15 sALS, n=14 controls) was extracted 
following the instructions of the supplier (RNeasy Mini 
Kit, Qiagen® GmbH, Hilden, Germany). PAXgene 
Blood RNA tubes were incubated overnight at 4°C in a 
shaker-plate to equilibrate the temperature and to 
increase yields, and then at room temperature for 2h 
before starting the procedure. RNA from frozen whole 
blood samples was extracted following the instructions 
of the supplier (PAXgene Blood RNA kit, PreAnalytiX, 
Qiagen® GmbH, Hilden, GE). RNA integrity and 
28S/18S ratios were determined with the Agilent 
Bioanalyzer (Agilent Technologies Inc, Santa Clara, 
CA, USA) to assess RNA quality, and the RNA con-
centration was evaluated using a NanoDrop™ Spectro-
photometer (Thermo Fisher Scientific). Complementary 
DNA (cDNA) preparation used the High-Capacity 
cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA, USA) following the protocol provided 
by the supplier. Parallel reactions for each RNA sample 
were run in the absence of MultiScribe Reverse 
Transcriptase to assess the lack of contamination of 
genomic DNA. TaqMan RT-qPCR assays were 
performed in duplicate for each gene on cDNA samples 
in 384-well optical plates using an ABI Prism 7900 
Sequence Detection system (Applied Biosystems, Life 
Technologies, Waltham, MA, USA). For each 10μL 
TaqMan reaction, 4.5μL cDNA was mixed with 0.5μL 
20x TaqMan Gene Expression Assays and 5μL of 2x 
TaqMan Universal PCR Master Mix (Applied 
Biosystems). Taqman probes used in expression assays 
were: allograft inflammatory factor (AIF1) 
(Hs00741549_g1) coding for IBA1, aldehyde dehydro-
genase 1 family member L1 (ALDH1L1) 
(Hs01003842_m1), glial fibrillary acidic protein (GFAP) 
(Hs00909233_m1), and CHI3L1 (Hs01072228_m1). 
Hypoxanthine-guanine phosphoribosyltransferase 
(HPRT1) was used as internal control for normalization 
of spinal cord samples, whereas β-glucuronidase (GUS-β) 
was used as the internal control for normalization of 
frontal cortex samples [90, 91]. Mean values of two 
house-keeping genes, glucuronidase beta (GUS-β) [92] 
and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) [93], were used as internal controls for 
normalization of whole-blood mRNA expression studies. 
 
The parameters of the reactions were 50°C for 2min, 
95°C for 10min, and 40 cycles of 95°C for 15sec and 
60°C for 1min. Finally, the capture of all TaqMan PCR 
data used the Sequence Detection Software (SDS 
version 2.2.2, Applied Biosystems). The double-delta 
cycle threshold (ΔΔCT) method was utilized to analyze 
the data results with Student’s-t test.  
Gel electrophoresis and immunoblotting 
 
Frozen samples of frontal cortex area 8 (n=6 sALS, n=6 
controls) and anterior horn of the spinal cord at the 
lumbar level (n=4 sALS, n=4 controls) were 
homogenized in RIPA lysis buffer composed of 50mM 
Tris/HCl buffer, pH 7.4 containing 2mM EDTA, 0.2% 
Nonidet P-40, 1mM PMSF, protease and phosphatase 
inhibitor cocktail (Roche Molecular Systems, USA). 
The homogenates were centrifuged for 20 min at 12,000 
rpm. Protein concentration was determined with the 
BCA method (Thermo Scientific). Equal amounts of 
protein (12μg) for each sample were loaded and 
separated by electrophoresis on 10% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
gels and then transferred onto nitrocellulose membranes 
(Amersham, Freiburg, GE). Non-specific bindings were 
blocked by incubation in 3% albumin in PBS containing 
0.2% Tween for 1h at room temperature. After washing, 
the membranes were incubated overnight at 4°C with 
antibodies against glial fibrillary acidic protein (GFAP) 
(dilution of 1:500; rabbit polyclonal monoclonal, 
MO761, Dako, Agilent, Santa Clara, USA), ionized 
calcium binding adapter molecule 1 (IBA1) for 
microglia (diluted at 1:1,000; rabbit polyclonal, 019-
19741, WAKO, Fujifilm, Tokyo, Japan), and YKL-40 
(diluted 1:200; goat polyclonal, AF-2599, R&D 
Systems, Minneapolis, MN, USA). Protein loading was 
monitored using an antibody against β-actin (42 kDa, 
1:30,000, Sigma). Membranes were incubated for 1h 
with appropriate HRP-conjugated secondary antibodies 
(1:2,000, Dako); the immunoreaction was revealed with 
a chemiluminescence reagent (ECL, Amersham). 
Densitometric quantification was carried out with the 
ImageLab v4.5.2 software (BioRad), using β-actin for 




De-waxed sections, 4μm thick, of the lumbar spinal 
cord (n=6 sALS, n=6 controls) and frontal cortex area 8 
(n=6 sALS, n=6 controls) were processed in parallel for 
immunohistochemistry. Endogenous peroxidases were 
blocked by incubation in 10% methanol-1% H2O2 for 
15min followed by 3% normal horse serum. Then the 
sections were incubated at 4°C overnight with anti-
YKL40 primary antibody (PA5-43746, ThermoFisher, 
Waltham, Massachusetts, USA) at a dilution of 1:200. 
Immediately afterwards,  the sections were incubated 
with EnVision + system peroxidase (Dako, Agilent, 
Santa Clara, CA, USA) for 30min at room temperature. 
The peroxidase reaction was visualized with diamino-
benzidine and H2O2. No signal was obtained following 
incubation with only the secondary antibody. Sections 
were slightly stained with haematoxylin. 
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Enzyme-linked immunosorbent assays (ELISA) in 
CSF 
 
YKL40 protein levels were measured using the 
MicroVue YKL40 EIA ELISA kit (Quidel, San Diego, 
CA, USA) following the manufacturer’s instructions. 
Receiver operating characteristic (ROC) curves and 
derived area under the curve (AUC) were calculated. 
The best cut-off value, sensitivity, and specificity were 
estimated based on the Youden index (point on a ROC 
curve providing the best balance of both sensitivity and 
specificity) [94]. NF-L levels were measured using the 
NF-light® (Neurofilament light) ELISA kit from 





The normality of distribution was analyzed with the 
Kolmogorov-Smirnov test. The unpaired Student’s t-test 
was used to compare each group when values followed 
normal distribution, and statistical analysis of the CSF 
protein data between groups was carried out using one-
way analysis of variance (ANOVA) followed by Tukey 
post-test, in both cases using the SPSS software (IBM 
Corp. Released 2013, IBM-SPSS Statistics for 
Windows, Version 21.0., Armonk, NY, USA). Graphic 
design was performed with GraphPad Prism version 
5.01 (La Jolla, CA, USA). Outliers were detected using 
the GraphPad software QuickCalcs (p < 0.05). The data 
were expressed as mean ± SEM, and significance levels 
were set at *P < 0.05, **P < 0.01, and ***P < 0.001, and 
tendencies at #P < 0.1. Pearson’s correlation coefficient 
was used to assess a possible linear association between 
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